Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab in advanced gastric or GEJ adenocarcinoma
NCT05942573Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of serplulimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
serplulimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05942573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942573.